We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.91B
AUM Growth
+$61.2M
Cap. Flow
+$64.4M
Cap. Flow %
2.22%
Top 10 Hldgs %
30.43%
Holding
226
New
26
Increased
31
Reduced
48
Closed
30

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$41M
2
ABT icon
Abbott
ABT
+$37M
3
MRNA icon
Moderna
MRNA
+$32.5M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
5
GILD icon
Gilead Sciences
GILD
+$26.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$60.5M
2
BDX icon
Becton Dickinson
BDX
+$22.1M
3
HUM icon
Humana
HUM
+$18.1M
4
TECH icon
Bio-Techne
TECH
+$16.1M
5
NVCR icon
NovoCure
NVCR
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.75%
2 Real Estate 2.99%
3 Industrials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
201
Axsome Therapeutics
AXSM
$10.8B
– –
-31,591
Closed -$2.57M
BHC icon
202
Bausch Health
BHC
$2.58B
– –
-101,412
Closed -$2.11M
DGX icon
203
Quest Diagnostics
DGX
$25.4B
– –
-109,659
Closed -$13.1M
DNTH icon
204
Dianthus Therapeutics
DNTH
$5.86B
– –
-12,027
Closed -$1.51M
ESPR
205
DELISTED
Esperion Therapeutics
ESPR
– –
-41,577
Closed -$1.08M
KYNB
206
Kyntra Bio
KYNB
$27.4M
– –
-7,771
Closed -$7.21M
INGN icon
207
Inogen
INGN
$184M
– –
-51,406
Closed -$2.3M
KPTI icon
208
Karyopharm Therapeutics
KPTI
$45.8M
– –
-4,383
Closed -$1.02M
MIST icon
209
Milestone Pharmaceuticals
MIST
$141M
– –
-253,610
Closed -$1.7M
NCNA
210
NuCana
NCNA
$5.62M
– –
-92
Closed -$2.07M
NVCR icon
211
NovoCure
NVCR
$1.82B
– –
-87,918
Closed -$15.2M
TGTX icon
212
TG Therapeutics
TGTX
$7B
– –
-133,269
Closed -$6.93M
VTRS icon
213
Viatris
VTRS
$20.3B
– –
-13,400
Closed -$251K
XNCR icon
214
Xencor
XNCR
$1.46B
– –
-148,231
Closed -$6.47M
ZYME icon
215
Zymeworks
ZYME
$1.63B
– –
-55,938
Closed -$2.64M
RVNC
216
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-213,808
Closed -$6.06M
AXNX
217
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-80,760
Closed -$4.03M
GRTS
218
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-419,005
Closed -$1.65M
IMGN
219
DELISTED
Immunogen Inc
IMGN
– –
-168,190
Closed -$1.08M
HARP
220
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-10,642
Closed -$1.77M
ABMD
221
DELISTED
Abiomed Inc
ABMD
– –
-10,812
Closed -$3.5M
AERI
222
DELISTED
Aerie Pharmaceuticals
AERI
– –
-66,688
Closed -$901K
KDMN
223
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-714,008
Closed -$2.96M
EIDX
224
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-20,000
Closed -$2.63M
BMY.RT
225
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-1,473,710
Closed -$1.02M
5 6 7 8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Tekla Capital Management held 226 positions worth $2.91B, up 2.1% from $2.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Tekla Capital Management's Q1 2021 filing shows 26 new, 31 increased, 48 reduced and 30 closed positions. Its largest new stake was Universal Health Services: 71,323 shares worth $9.51M. The largest sale was Alexion Pharmaceuticals, an estimated $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2021 buy was Universal Health Services: 71,323 shares worth $9.51M.
  • Tekla Capital Management added most to Elevance Health in Q1 2021, an estimated $41M increase.
  • Tekla Capital Management's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $60.5M.
  • Tekla Capital Management fully exited NovoCure in Q1 2021, selling an estimated $15.2M.
  • Tekla Capital Management's ten largest holdings make up 30% of its $2.91B portfolio in Q1 2021.
  • Tekla Capital Management opened 26 new positions and closed 30 in Q1 2021.
  • Tekla Capital Management's portfolio value rose 2.1% quarter-over-quarter to $2.91B.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.